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Abstract 
Irritable bowel syndrome (IBS) is the most prevalent functional gastrointestinal 
disorder (FGID) phenotypically characterized by chronic abdominal discomfort, pain 
and altered defecation patterns. It is postulated that the pathophysiology of IBS is 
multifactorial, albeit with a significant genetic component. To date, studies using 
various methodologies, ranging from family and twin studies to candidate gene 
approaches and genome wide association studies have identified several genetic 
variants in the context of IBS. Yet, despite enlarged sample sizes, increased statistical 
power and meta-analyses in the more recent years, positive associations are still 
scarce and/or have not been reproduced. Moreover, epigenetic and pharmacogenetic 
approaches remain in their infancy. A major hurdle is the lack of large homogenized 
case-control cohorts recruited according to standardized and harmonized criteria. The 
COST Action GENIEUR BM1106 (GENes in Irritable Bowel Syndrome Research 
Network EURope, www.GENIEUR.eu) was established in order to address these 
obstacles. In this review, the epi-/genetics Working Group of GENIEUR reports on 
the current state of the art in the field, highlights fundamental flaws and pitfalls in 
current IBS epi-/genetics research and provides a vision of how to tackle and improve 
epi-/genetics approaches in this complex disorder in the future. 
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Introduction  
Irritable bowel syndrome (IBS) affects up to 20% of the western population1. 
Characteristic symptoms include chronic discomfort and abdominal pain associated 
with altered bowel habits in the absence of an organic cause2. As there are no 
biomarkers available for IBS, it is a symptom based diagnosis made according to the 
Rome III criteria (www.romecriteria.org). According to the defecation pattern, IBS is 
subdivided into the following subtypes: diarrhea-predominant (IBS-D), constipation-
predominant (IBS-C), a mixed subtype (IBS-M) and un-subtyped IBS (IBS-U)3. 
Anxiety and depression are common comorbidities in IBS, reflecting the complex 
relationship between visceral sensation and psychological perceptions that are 
mediated via the brain-gut axis. IBS patients also report altered somatic pain 
perception4, 5 and other somatic pain syndromes such as migraine, fibromyalgia and 
chronic fatigue syndrome are over-represented 6 7. Direct medical expenses associated 
with outpatient visits, hospitalisation, diagnostic tests and ineffective treatment lead to 
a marked economic burden to the healthcare system with an estimated annual total 
cost of €41 billion in the EU.8 Indirect costs of IBS related to work absenteeism and 
lower productivity are also considerable. Our knowledge of the pathophysiology of 
IBS, mainly due to its multifactorial origin, remains limited and there is a current 
paucity of efficacious therapies.  
Environmental factors such as psychological stress9, diet, and smoking,  infectious 
gastroenteritis leading to post-infectious IBS (PI-IBS)10 as well as alterations in the 
gut microbiota, produce a complex interaction with genetic variants dispersed in the 
human genome and leading to individual epigenetic prints. These factors may 
contribute to central and peripheral (neurobiological) intermediate phenotypes (brain 
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and enteric nervous system (ENS) function) influencing the brain-gut axis and may 
consequently manifest as central behavioural and gastrointestinal (GI) intermediate 
phenotypes and thereby predisposing to IBS and its comorbid conditions (Figure 1).10-
12 The role of intrinsic factors (genetics, epigenetics, sex hormones, coping 
mechanisms) in IBS has been studied to a lesser extent.  
IBS heritability: Family and twin studies 
 Several studies have reported the familial clustering of IBS, thus suggesting an 
inherited component. 13 14 15 16 17 18 19 One of the first studies to examine the role of 
heritability in IBS, demonstrated that one-third of patients had a relative with IBS, 
even in patients without a concurrent psychiatric diagnosis20. Other studies have 
shown that having a first-degree relative with IBS may be predictive of IBS and 
increased IBS risk among first-, second-, and third degree relatives, in the absence of 
an interaction of gender or age at symptoms onset, thereby providing evidence that a 
family history of IBS is a potential predictor of personal IBS risk 18 with relatives of 
IBS patients had a two-threefold heightened risk of having IBS. Moreover, familial 
clustering was observed to be present irrespective of the subtype of IBS and the 
known environmental risk factors for IBS are also common in IBS families15.  
Twin studies also support the notion that IBS may be a multifactorial disorder with 
genetic as well as environmental contributors. To date, at least five twin studies 
estimated the genetic heritability in IBS as between 22–57%. 21 There is a higher 
concordance rate for IBS among monozygotic compared to dizygotic twins. 13 22 23 24 
Twin studies using a co-twin control design have revealed restricted fetal growth in 
the low range of birth weight (<2500 gram) as the common contributor to 
development of IBS and symptoms of anxiety or depression. These observations have 
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led to the proposal that dysfunction within the hypothalamic-pituitary-adrenal (HPA) 
axis may link restricted intrauterine growth with IBS risk as well as the frequently 
encountered comorbidity between IBS and anxiety and depression.22, 25 These findings 
provide the rationale for the exploration of the role of the expression and epigenetic 
prints of genes involved in the HPA axis, such as the corticotropin releasing factor 
(CRF) signaling pathways genes, as outlined below. 26 27  
Nevertheless, it should be noted that despite the consistent observation of familial 
clustering of IBS coupled with the increased prevalence amongst monozygotic 
compared to dizygotic twins, such factors could be explained, at least in part, by 
shared environmental contributors. Indeed, several studies have demonstrated the 
importance of social learning as an explanatory factor of IBS development later in 
life, 28, 29 although these findings are not universal across the literature 22, 23, 30. Based 
these lines of converging evidence we propose that IBS is a multifactorial, complex 
genetic disorder arising from the interaction between both genetic and environmental 
factors. The aim of this review is to summarize the current state of the art in the field 
of genetics and epigenetics research in IBS and its comorbid conditions, to highlight 
the fundamental flaws and pitfalls in unraveling the molecular mechanisms of IBS 
and to share our view how to address these difficulties and therefore improve the 
approaches to better define epi-/genetics mechanisms in this multifactorial disorder in 
the future. 
Molecular genetics approaches 
Despite considerable evidence pointing to the contribution of genetic factors in the 
pathogenesis of, and predisposition to, IBS, the precise genetic basis remains elusive. 
Hitherto, the majority of studies have examined the effects of a few single nucleotide 
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polymorphisms (SNPs) in hypothesis-driven candidate approaches, while two studies 
performed a hypothesis-free gene-naive genome wide association study (GWAS) (see 
below). 
Candidate gene studies 
Genetic variants in the serotonergic system 
Based on the hypothesis that disturbances in 5-hydroxytryptamine (5-HT) metabolism 
and/or signal transduction via the brain-gut axis contribute to altered sensorimotor 
function in the GI tract, it is not surprising that the serotonergic system has been 
extensively studied. In particular, the homozygous genotype of the short (S) allele of 
the promoter length polymorphism 5-HT transporter linked polymorphic region (5-
HTTLPR), a region upstream of the serotonin reuptake transporter (SERT) gene 
SLC6A4, has been reported as being associated with IBS-D and IBS-C (Table 1).31 32 
33 The S allele is a functional polymorphism that differentially influences SLC6A4 
transcription, presumably reducing SERT expression and 5-HT re-uptake.34 Indeed, 5-
HT levels have been found to be increased in rectal biopsies of IBS-D patients 33 and 
5-HT levels were significantly increased in those who were homozygous for the S 
allele in comparison to carriers of the long (L) allele. Of note, the S allele is also 
associated with the disorders that are comorbid with IBS such as  depression and 
anxiety 34 35 36 as well as higher neuroticism/anxiety scores, sympathetic tone, lower 
parasympathetic tone and cortisol levels.37 Moreover, S allele carriers and those 
homozygous for the S allele also have differences in the central processing of visceral 
pain demonstrating increased amygdala activity in studies applying an emotional 
paradigm and increased cerebral activity during colorectal distention respectively.38 39 
These findings therefore imply a high susceptibility to negative emotional memory in 
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S/S carriers providing further support to  the biopsychosocial model of IBS in which 
alterations in psychological state may contribute to enhanced visceral pain perception.  
Further evidence for an abnormal serotonergic signaling in IBS and comorbid 
conditions, is providing by studies examining the role of serotonin type 3 receptors (5-
HT3R) encoded by HTR3 genes. 5-HT3Rs influences GI function, in particular, 
peristalsis and secretion, and are relevant in emotional processing, mood and visceral 
perception. Moreover 5-HT3R antagonists, such as ondansetron and alosetron, are 
beneficial in the therapy of IBS-D.40 41 42 SNPs in the HTR3A (rs1062613), HTR3C 
(rs6766410) and HTR3E (rs62625044) genes have been reported to be associated with 
IBS-D (Table 1).43 44 45 SNPs rs1062613 and rs62625044 in HTR3A and HTR3E 
localize outside the coding region and seem to impair translation of the receptors, 
thereby causing up-regulation of receptor expression43, and their role in IBS-D has 
recently been delineated.45 Moreover, rs1062613 in HTR3A was found to be 
associated with hypersensitivity in GERD patients and dyspepsia.46 47 Initially, it was 
reported to be associated with major depression and ‘harm avoidance’, an inherited 
temperamental trait associated with depression and anxiety.48, 49 In a recent study it 
has been shown to be correlated with IBS symptom score and anxiety.50 Furthermore, 
rs1176744 in HTR3B was previously associated with anorexia and depression,51 52 53 
and subsequently with IBS, in particular with an increased anxiety score and 
alexithymia20 (Table 1). Of note, in a recent IBS-GWAS, SNPs in HTR3E and 
SLC6A4 were nominally associated with IBS.54  
Furthermore, functional magnetic resonance imaging (fMRI) studies have shown 
decreased amygdala and prefrontal cortex activity in minor allele (T) carriers of 
rs1062613 in HTR3A in an emotional paradigm.55 In addition, a more recent fMRI 
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study revealed that carriers of the major allele (C ) have increased responsiveness 
within the amygdala to emotional and non-emotional stimuli, higher anxiety and IBS 
symptom scores.50 Furthermore, carriers of rs1176744 in HTR3B presented with 
significantly higher activity of the right amygdala, left insula and left orbitofrontal 
cortex in a rectal distension paradigm (Table 1). Consequently, HTR3 variants seem to 
influence gut-derived responses in brain regions relevant for negative emotion, body 
recognition, and discrimination of stimulus.39 In addition, rs1176744 has recently 
been found to associate with pain catastrophising, a coping style characterized by 
excessively negative thoughts and emotions in relation to pain.56 
Taken together, these data support the proposal that disruptions within serotonergic 
signaling are relevant at least in a subgroup of IBS, presumably IBS-D. However, 
additional SNPs in genes of the serotonergic such as tryptophan hydroxylase TPH1 as 
well as the serotonin receptor genes HTR2A and HTR2C have been found to be 
associated with IBS in single studies, albeit yet not replicated in additional cohorts 
(Table 1).  
Genetic variants in genes related to neuronal function 
Approximately 60% of IBS patients suffer from increased visceral perception20 which 
is potentially mediated by altered neuronal function including sensitisation of 
nociceptors on afferent nerves, increased nociceptive signaling at the level of the 
spinal cord or altered brain function. In fact, associations between SNPs in the 
voltage-gated sodium channel NaV1.5 gene SCN5A and IBS have been reported57. 
These data provide evidence that a subset of IBS patients may suffer from SCN5A-
encoded NaV1.5 ion channelopathy, leading to altered neuronal excitability and 
therefore potentially contributing to motility disturbances and heightened pain 
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perception. Moreover, rs2349775 in another gene relevant to neuronal function, 
neurexophilin 1 (NXPH1), was associated with IBS-D.58 This SNP was previously 
linked to neuroticism59, yet its functional relevance in IBS remains elusive. Other 
potentially relevant variants in neuronal genes reside in the adrenergic receptor genes 
ADRA2A and 2C 60 61 62 as well as in the genes encoding catechol-O-
methyltransferase (COMT), brain-derived neurotrophic factor (BDNF), mu opioids 
receptor (OPMR1), cannabinoid receptor type 1 (CNR1) and fatty acid amide 
hydrolase (FAAH) (Table 1). 
Genetic variants in genes implicated in intestinal barrier function 
Differential expression signatures of genes encoding tight junction proteins (occludin 
and zonula 1, claudin) have recently provided evidence to support the hypothesis of 
impaired intestinal barrier function in IBS-D 63 64 65 while SNPs in cadherin 1 (CDH1, 
a tight junction protein, also associated with Crohn’s disease) is associated with PI-
IBS.66 In addition, rs1783796 in CDC42 (cell division cycle 42), a small guanosine 
triphosphate-ase protein that controls the distribution of tight junction proteins, has 
been linked to IBS-C58. Nevertheless, further studies are required to identify and 
validate SNPs in barrier related genes in order to define subpopulation of IBS patients 
whose pathogenesis is in part related to intrinsic barrier impairment. 
SNPs in genes related to immune function 
Low grade immune activation or dysregulation has been proposed as underlying 
mechanism of IBS, especially following an episode of acute gastroenteritis.12 SNPs in 
genes involved in immune modulation and inflammation may predispose to IBS, even 
without previous GI infection.67 68, 69 
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To date, SNPs in TNFSF15 encoding the tumor necrosis factor (TNF) ligand 
superfamily member TL1A, have been consistently demonstrated to be associated 
with IBS68 Associations for TNFSF15 were shown within the different IBS subtypes: 
IBS-C,70 IBS-D71 and IBS-A.58 Lately, rs4263839 in TNFSF15 was nominally 
associated in the first large IBS-GWAS. 54 TNFSF15 is implicated in inflammatory 
bowel disease (IBD) and increased gene product expression has been reported in the 
intestinal biopsies of patients with IBS as well as Crohn’s disease and the skin of 
pateints with psoriasis.70 71 72 73 74  TL1A has been shown to enhance immune cell 
function and cytokine production.75-77 Consequently, TNFSF15 risk variants may alter 
disease susceptibility through differential modulation of pro-inflammatory and/or 
anti-bacterial responses, thereby contributing to the pathophysiology of a diverse 
array of immune-mediated human diseases, including IBS.  
Various earlier studies suggested SNPs in interleukin-10 (IL10) and TNF-alpha 
(TNFA) are associated with IBS.78 However, the reported findings were inconsistent 
and not reproducibly replicated (Table 1). A meta-analysis, examining 16 previously 
analysed SNPs in genes involved in immune response, did not shown an association 
between any of the tested SNPs, except for TNFSF15, thus indicating a minor role for 
immune-associated genes in IBS.69  
Whole genome analyses 
To date, only two studies have utilised a GWAS approach to delineate the genetic 
contribution to the pathophysiology of IBS. Firstly, a small pilot GWAS in 172 IBS 
cases and 1,398 controls reported association on chromosome 10 in the protocadherin 
15 gene (PCDH15) but this finding could not be confirmed in additional samples.79 
Secondly, using a similar approach, Ek et al.54 analysed 11 326 Swedish twins includ-
ing 534 IBS cases and 4932 asymptomatic controls and validated their findings in co-
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horts from various centres from Europe, the USA and Australia. One locus, at 7p22.1 
encoding for the genes KDELR2 (KDEL endoplasmic reticulum protein retention re-
ceptor 2) and GRID2IP (glutamate receptor, ionotropic, delta 2 (GRID2) interacting 
protein), was significantly associated with IBS risk in the index GWAS and all repli-
cation cohorts, reaching  a p-value of 9.31×10-6 in a meta-analysis of all datasets. Ex-
pression analysis revealed a trend for increased mucosal KDLER2 mRNA levels in 
IBS cases compared with controls. However, knowledge gaps remain as to what ex-
tent these findings contribute to the symptomatology of IBS and what the precise role 
of these genes is in IBS intermediate traits, and if these candidate genes are causative 
or represent another gene or even mechanism that account for the observed signal at 
7p22.1.  
Epigenetics 
Environmental factors such as early or childhood trauma, physical and psychological 
stress, exposure to pathogens as well as changes in the gut microbiota may play a cru-
cial role in the clinical manifestations of IBS. Epigenetic molecular mechanisms, 
which include DNA methylation and histone de-acetylation, are implicated in the 
stress related dysregulation of the HPA axis80. The investigation of epigenetic changes 
in IBS and related disorders remain in their infancy, although several animal studies 
reported decreased mRNA levels of candidate genes correlating with altered patterns 
of histone acetylation and DNA methylation at the relevant promoter regions.80 One 
preclinical example, applying a stress model reported differential methylation of the 
genes encoding the glucocorticoid receptors (Nr3c1) and corticotropin-releasing fac-
tor receptor 2 (Crfr2), which inversely correlated with their respective gene expres-
sion levels. This study further demonstrated the involvement of central epigenetic 
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mechanisms in regulating stress-induced visceral hypersensitivity and provides a ro-
bust rationale for further work exploring the epigenetic mechanisms that may contrib-
ute to IBS-like symptomatology81. A recent animal study showed that the susceptibil-
ity to stress-triggered visceral hypersensitivity can be transferred across generations, 
dependent on maternal care82. Indeed, cross-fostered pups adapted to the phenotype of 
the foster mother: pups of normosensitive dams nursed by hypersensitive dams 
showed visceral hypersensitivity to distension at adult age and vice versa presumably 
by differential epigenetic prints82.  
To date, only a small number of microRNA studies have been performed in IBS (Ta-
ble 2). Notably, recent reports have shown that a subset of patients with IBS-D dis-
play altered expression of specific non-coding microRNAs (hsa-miR29a, hsa-miR29b 
and hsa-miR-199a). Up-regulation of miR-29a/b in the intestinal mucosa decreased 
levels of glutamine synthetase (GLUL),83 an important regulator of intestinal permea-
bility and homeostasis, and claudin1 (CLDN1) as well as NF-kappa-B-repressing fac-
tor (NKRF). In turn, down regulation of miR-199 correlated with an increased expres-
sion of the transient receptor potential vanilloid type 1 (TRPV1) going along with in-
creased visceral sensitivity. 84, 85 Therefore, silencing of the miR family miR-29 or 
applying miR-199a may have important therapeutic implications for selected IBS pa-
tients with symptoms caused by increased intestinal permeability or hypersensitivity. 
Preliminary data also indicate increased levels of circulating hsa-miR-150 and hsa-
miR-342-3p in the blood of IBS patients, compared to healthy controls.86 Interesting-
ly, hsa-miR-150 has been described to be associated with IBD and pain, whereas hsa-
miR-342-3p has been predicted to interact with mRNAs involved in pain signaling, 
colonic motility, and smooth muscle function. Interestingly, hsa-miR-342-3p has been 
found to be up-regulated in bladder pain syndrome.87 In actual studies, hsa-miR-103, 
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hsa-miR-16, hsa-miR-125b, hsa-miR-338, hsa-miR-502, and hsa-miR-92 expression 
was found to be diminished in the intestinal mucosa of IBS patients (Martinez, Niesler 
and Santos, unpublished data). In addition, Niesler’s group has identified IBS-D asso-
ciated variants in the serotonin receptor genes HTR3E and more recently HTR4b, with 
SNPs c.*76G>A and c.*61T>C leading to disturbed regulation of hsa-miR-510 and 
hsa-miR-16, respectively. These two miRNAs have been shown to have impaired 
binding ability to target regions, leading to a reduction in the translational repression 
and presumably therefore an increased expression of the target genes.43 88  
Complex genetic data analysis 
Genetic and epigenetic data analyses using either hypothesis free data driven (whole 
genome) or pathway driven (gene-specific) approaches have strengths and limitations 
when applied to IBS. Firstly, GWAS are far more informative as they interrogate the 
whole human genome, irrespective of hypothetic pathway involvement.54, 79 However, 
despite the high prevalence of IBS in the population89 the current number of 
individuals included in the existing GWAS studies only allows limited statistical 
power, following adjustments for multiple testing. This GWAS limitation is 
particularly augmented with respect to IBS, since genetic loci might be sub-type, sex, 
or clinical phenotype specific21, 89, 90 and the need for subgroup analyses further 
reduces statistical power. On the other hand, pathway driven approaches allow for 
increased statistical power but they are not investigating pathways whose role in IBS 
has not yet been revealed or suspected. 
However, the problem of statistical power and limited subject counts, can in part be 
addressed by the use of validation and replication data sets54, 79 as well as restricted 
analysis of particular sub-phenotypes.91 This highlights the importance of the 
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availability of well-characterized case control cohorts for validation/replication 
studies and sub-phenotyping, especially in cohorts of different ethnic origin.57 In 
order to constrain the statistical burden of multiplicity in association studies, one 
needs to assume an additive penetrance model. Additive, dominant and co-dominant 
(Pearson 2 degrees of freedom) association tests all show a similar statistical power, 
and study sample sizes are often too small to identify recessive effects. Allele tests are 
thus not recommended because their alpha levels depend on Hardy-Weinberg 
equilibrium.92 93 Gene x environment interaction analyses can help delineate the 
relationships between genetics, environmental factors, and IBS, however, such 
investigations must rely uniform thorough and detailed data collection as well as on 
large well phenotyped sample sizes in multi-centre studies.  
Pharmacogenetics  
A better understanding of the genes that predispose to the development of IBS may 
pave the way in the future for pharmacogenetic approaches, thereby enabling 
personalisation of treatment tailored by SNP based prediction of pharmacotherapeutic 
response. However, a reverse approach might utilize knowledge on individual 
variation in drug treatment of IBS to generate better insight to IBS underlying 
pathophysiology. 
Serotonergic drug effects  
As outlined above, 5-HT is central in the regulation of GI function and may manifest 
in symptoms such as diarrhea.94 5-HT3 receptor antagonists, such as alosetron and 
ramosetron, reduce symptoms in IBS-D, retard GI transit, increase fluid absorption 
and reduce pain. 95 96 The 5-HTTPLR S/L polymorphism in SLC6A4 has been shown 
to correlate with clinical response to alosteron in IBS-D, thereby altering the 
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risk:benefit ratio with this class of compounds.97 To what extent HTR3 SNPs may 
influence ’setron’ response is presently unknown. Treatment by tegaserod, a 5-HT4 
receptor agonist, used for the treatment of IBS-C was also shown to correlate with this 
SLC6A4 polymorphism. More specifically, the L/L genotype increases the sensitivity 
of constipation and causes a lower response to treatment with tegaserod.98  
Adrenergic and opioidergic drugs 
The clinical response to clonidine, an α2-adrenergic agonist, is modulated by gene 
variations in α2-adrenergic receptor gene ADRA2A, such as rs1800544, a SNP 
reportedly associated with gastric accommodation and rectal sensations of gas 
bloating and defaecatory urgency.99 The cannabinoid receptor agonist dronabinol 
decreases fasting colonic phasic motility and increases colonic compliance, especially 
in IBS-D and IBS-M patients. However, the effectiveness of dronabinol is correlated 
with rs806378 in cannabinoid receptor 1 (CNR1). 100 101 This SNP is also associated 
with colonic transit in IBS-D and sensation rating of gas. 102 Additionally, a variant in 
the fatty acid amide hydrolase gene FAAH, rs324420, and treatment with dronabinol 
leads to acceleration of proximal colonic motility in patients with IBS-D or IBS-M103.  
Bile acids 
Genetic variants in the klotho beta gene KLB and the fibroblast growth factor receptor 
4 gene, FGFR4 are associated with accelerated colonic transit in patients with IBS-D. 
These variants also correlate with the colonic transit response to chenodeoxycholic 
acid in IBS-C,104 and to colesevelam in IBS-D patients.105 
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Conclusions and future perspective 
The delineation of the genetic factors that are involved in the aetiopathophysiology of 
IBS remains challenging due to the marked heterogeneity of patients’ populations as-
signed to the umbrella diagnosis of IBS. Recent genetics findings support current 
models of IBS pathogenesis such as altered neuronal signal transduction, impaired 
immune response and intestinal barrier dysfunction. However, the majority of studies 
lack the necessary power to apply different predisposing risk models, thereby leading 
to conflicting or potentially false positive results. In addition, inconsistency of associ-
ation findings might have been blurred by the different expertise and focus of the re-
cruitment centres (e.g. psychosomatics, hypnotherapy, inflammatory bowel disorders) 
thereby introducing a centre-specific bias. Furthermore, patients have been recruited 
applying non-uniform symptom classifications (Rome I/II/III) and comorbidity is 
rarely adequately assessed. Moreover, control individuals often have not been exclud-
ed for IBS and/or comorbid conditions, therefore representing an additional source of 
bias. This is reflected by contradictory association findings with overall IBS, and its 
current subtypes, implying that more extensive studies on larger cohorts and/or better-
stratified phenotypes are warranted.  
Moreover, the currently used symptom-based classification does not guarantee that 
the groups of patients studied were indeed all afflicted with the same disease and aeti-
opathogenetic mechanism. In fact, several peripheral mechanisms that contribute to 
the development of IBS with constipation phenotype may also be involved in other 
diseases, such as, slow transit constipation, intestinal pseudo-obstruction, and 
idiopathic megacolon. A diarrhea phenotype may share susceptibility genes to food 
intolerance, disaccharidase deficiency, bile acid malabsorption, small intestinal bacte-
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rial overgrowth, gluten sensitivity, increased mucosal permeability, immune activa-
tion, or accelerated colonic transit due to a motility disorder.  
It must be stressed that genetic association frequently does not imply phenotype cau-
sation and the SNPs associated with IBS may simply implicate a region in the genome 
where relevant disease causing variants might reside.  
Epigenetic findings support the postulation regarding the role of neuronal pathways 
and impairment of intestinal barrier function in the pathogenesis of IBS and suggest 
their utility for diagnosis and/or treatment of those affected. However, the manner in 
which these genetic and epigenetic alterations might impact structure and function of 
GI tissue as well as the brain-gut crosstalk and stress axis leading to the distinct clini-
cal phenotypes remains unclear. Replication studies in adequately powered independ-
ent cohorts of well characterized IBS patients enabling correlation to sub-phenotypes 
including comorbid conditions are clearly warranted. These are of tremendous im-
portance as these may pave the way for pharmacogenetics approaches in the future. 
Based on current collections of research data, one of the most evident shortcomings of 
contemporaneous research in IBS is the lack of a comprehensive multidisciplinary 
integrative approach to investigate the different pathophysiological features using 
unified phenotyping tools. Such an approach seems crucial to facilitate dissection of 
the various factors involved in the pathogenesis of IBS. It is on this premise that a 
number of multidisciplinary experts from across Europe joined forces to overcome 
this issue by developing detailed phenotyping strategies in order to allow stratification 
of genetic data in sub-phenotypes of IBS patients, thereby increasing power and effect 
size of the associated variants. Furthermore, additional parameters, the collaborative 
has developed protocols for the measurement of intermediate phenotypes and 
quantitative traits which are mandatory to dissect epi-/genetic patterns underlying IBS 
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and subsequently correlate these with symptom complexes. Obviously, this can only 
be achieved by detailed meticulous phenotypic characterisation of patients based on 
clinical examination, specific questionnaires that assess GI symptoms and psychiatric 
comorbidity, personality traits, somatisation status, assessment of physiological 
parameters and tissue sampling for follow-up of expression changes in candidate 
genes. In addition, to avoid bias introduced by IBS cases within control populations, 
such controls should also be evaluated using the same tools as the cases. In 
conjunction to such detailed phenotyping, family history of FGID and crucial known 
environmental predisposing factors (stress, infection, nutrition) should be assessed 
and thereby the identification of distinct patient subgroups will facilitate the 
stratification of epi-/genetics data in combination with environmental factors. 
Therefore, the major goal of the COST (COoperation in Science and Technology) 
Action GENIEUR BM1106 (GENes in Irritable Bowel Syndrome Research Network 
EURope, www.GENIEUR.eu) is to establish harmonized criteria and a standard 
protocol in order to recruit a large set of well characterized patients and controls. A 
further goal of GENIEUR is the establishment and development of an infrastructure 
that will facilitate future multicenter studies in which not only blood samples for epi-
/genetics and stool samples for microbiota studies will be archived but also gut tissue 
samples from various regions for follow up of epi-/genetics findings.  
We also propose to investigate in depth the contribution of copy number variations 
and rare variants assessed by next generation sequencing applied to the entire exome 
or genome to the pathogenesis of IBS. The emerging technologies for massive parallel 
sequencing, combined with reductions in costs coupled with the development of ad-
vanced analytical tools, leave little doubt that these new technologies will comple-
ment and enhance current efforts focused on improving the field’s understanding of 
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role of genetics of IBS, in a manner similar to what has been achieved in complex GI 
disorders such as Crohn's disease106, 107 . 
In these studies not only well characterized cohorts but also family and twin studies 
should be taken into account. Thus the utilisation of hypothesis free approaches may 
lead to the identification of novel, and as yet un-anticipated, pathophysiological 
mechanisms across the disorder. 
In particular, further exploration of family clustering of FGID might provide useful 
insights into shared pathogenic pathways and shared environment. The power of this 
approach was shown in a recent study, where a SNP in GUCY2C (guanylate cyclase 
C, GC-C) which regulates secretion in enterocytes, co-segregated with diarrhea in all 
affected family members, some of whom were diagnosed with IBS, further underscor-
ing the potential relevance of this signaling pathway.108  
In addition, functional validation of the effect of any detected genetic variants is 
essential in order to provide an in-depth insight into the potential pathophysiological 
role of the respective epi-/genetic changes. This effort requires the establishment of 
appropriate cell culture models as well as the follow up of expression changes of 
regulatory variants in relevant tissues. 
The outcome of integrative genetics and epigenetics studies may help to define novel 
IBS subgroups which will facilitate the development of enhanced diagnostics and 
novel treatment options, specifically targeting towards the affected pathways. The 
identified genetic variants and epigenetic markers as well as miRNAs may serve as 
biomarkers for interventional studies and pharmacotherapy in order to individualize 
therapy in the future and ultimately improve patient outcomes. 
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Figure 1. Multiple layers of complexity on genetic, epigenetic and environmental 
level contribute to the pathogenesis of IBS and comorbid conditions. A diverse array 
of environmental factors interact with underlying genetic variants in IBS – these 
predisposing genes lead to an alteration in structure and/or function which itself is 
represented within myriad of (neurobiological) intermediate phenotypes (central and 
enteric nervous systems function) and influencing the brain-gut axis. Consequently, it 
may manifest as central behavioural and GI intermediate phenotypes and thereby 
predispose to the IBS as well as comorbid conditions. 
Figure 2. IBS related pathways based on genetic and epigenetic findings including 
potential pharmacogenetic targets. 
 
Table 1. Summary genetic association data in IBS. 
Table 2. Summary epigenetic data in IBS. 
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Bullet Points 
 
• Genetic studies in IBS range from family and twin studies to candidate gene 
approaches and genome wide association studies  
• Despite enlarged sample sizes, increased statistical power and meta-analyses positive 
associations are still scarce and/or have not been reproduced. 
• Epigenetic and pharmacogenetic approaches are in their infancy. 
• A major pitfall is the lack of large homogenized case-control cohorts recruited 
according to standardized and harmonized criteria.  
 
 1
Table 1 
 
Gene SNP 
database 
number (RS) 
HGVS 
nomenclature 
Functional 
variant 
3 IBS IBS-subtype Association with 
comorbid disorder or 
other quantitative 
traits 
Case 
Group 
(N) 
Control 
Group 
(N) 
Country of 
origin 
Reference 
SNPs in genes in serotonergic pathways 
SLC6A4 rs4795541* g.28564359_285643
60insG 
c.-1950_-1949insC No association  1034
 
1377
 
USA, UK, 
Turkey, 
China, Korea 
 
31
 
LS genotype with IBS-D  54 91 Turkey 32
SS genotype with IBS-C 
and LS genotype with 
IBS-D 
 
SS genotype with IBS-D  194 448 USA 33
SS genotype with IBS-D  190 437 Korea 34
S allele with M-IBS, but 
not IBS overall 
 50 53 USA 35
SS genotype with IBS-C  151 100 India 36
SS genotype with IBS-D 
 
Higher 5-HT level in rectal 
biopsies 
150 252 India 37
 
No association  33 56 Korea 38
No association  256 120 USA 39
LL genotype with IBS-C 
 
 81 48 China 40
LL genotype with IBS-C 
 
 87 96 China 41
LL genotype with the total IBS, 
IBS-C and IBS-M 
 
 
99 171 Korea 42
SS genotype with 
depression in IBS; LL 
genotype with decr. in 
social functioning in IBS 
133 - USA 43
SS genotype with 
absence of IBS 
symptoms 
LS/SS with the higher pain 
rating 
122 39 USA 44
Low frequency of SS 
genotype in males 
with IBS   
 196 92 UK, Germany 45
NA S allele with personality 
disorders in females 
NA 374 USA 46
 2
NA S allele with higher 
neuroticism/anxiety 
scores, greater 
sympathetic tone, higher 
cortisol level  
NA 120 UK 47
intron 2 (STin2 
VNTR) 
Short VNTR with 
depression in IBS 
21 men 
and 117 
women 
- USA 43
12/10 genotype with 
IBS 
 
 81 48 China 40
rs25531 g.28564346T>C c.-1936A>G G allele with IBS  186 50 USA 48
HTR2A rs6313 g.47469940G>A c.102C>T C allele with a high 
risk of IBS 
TT genotype with more 
severe pain in IBS 
54 107 Turkey 49
rs6311 g.46897343C>T c.-1438G>A A allele with a high 
risk of IBS 
Low frequency of A allele 
with depressive disorders 
in IBS 
95 - Poland 50
HTR2C 
 
 
 
rs6318 g.114731326C>G c.68C>G Low frequency of G allele 
and GG genotype with 
anxiety disorders in IBS 
95 - Poland 50
HTR3A rs1062613 g.113975284T>C  c.-42T>C With IBS-D  200 100 UK, Germany 51
C/C genotype with 
greater IBS symptom 
scale 
C/C genotype with 
amygdale responsiveness 
and anxiety ratings 
26 29 USA 52
HTR3B rs1176744 g.113932306A>C  c.386A>C With IBS particularly anxiety score 
and alexithymia 
119 229 Japan 20
HTR3C rs6766410 g.184056974C>A c.489C>A With IBS-D  200 100 UK, Germany 51
HTR3E rs62625044 g.184106769G>A  c.*76G>A With IBS-D in females  319 295 UK, Germany 53
T allele with IBS-D and 
GA genotype with female 
IBS-D 
 300 450 China 54
TPH1 rs4537731 
 
g.18047335T>C c.-6526A>G With diarrhea in IBS  199 79 USA 55
 With IBS-related cognition 
and diseases perception 
199 USA 56
rs211105   g.18033757T>G c.332-383A>C  
rs684302 g.18038806C>T c.117+1840G>A With quality of life in IBS
rs1800532 g.18026269G>T 
(c.606+221C>A) 
c.218A>C  
SNPs in genes related to neuronal function 
COMT rs4680 g.19951271G>A c.472G>A 158Met allele with IBS-C  645 323 USA 15
 
Val/Val genotype with Val/Val genotype with  70 867 Sweden 57
 3
IBS overall 
 
increased stool 
frequency 
BDNF rs6265 g.27658369C>T c.196G>A Met with ‘psychiatric’ 
symptoms ratings  
 
645 323 USA 15
 
OPRM1 rs1799971 g.154360797A>G c.118A>G G allele with IBS-M G allele IBS-D females  645 323 USA 15
 
 
CNR1 3'-UTR CNR1   (AAT)n >10/>10 genotype 
with IBS 
 
 292 298 China 58
 162 423 USA 59
With IBS-D Gas (not pain) sensation 
rating  
74 24 USA 60
rs806378 g.88859551C>T c.-206-2026G>A TT genotype with faster 
colonic transit (at 24 & 48 
h) and gas (not pain) 
sensation rating in IBS-D 
74 24 USA 60
 With IBS-D  445 228 USA 60
FAAH rs324420 g.46870761C>A c.385C>A A allele with IBS-M A allele with IBS-D A allele with faster colonic 
transit with IBS-D 
270 252 USA 60
SCN5A   p.A997T-
Other missense 
mutations: 
p.I94V,p.T220I, 
p.G615E, p.T630M, 
p.P648L,p.G1158S 
p.E1780G, 
p.A1870D 
10% of IBS-D are 
mutation carriers 
30% of IBS-C are 
mutation carriers (loss of 
function haplotype) 
 584 1380 USA, Sweden, 
Italy Greece 
61
rs137854608 g.38651267C>T c.892G>A With IBS  49 1500 USA 14
ADRA2A rs1800544 g.112836503G>C c.-1252G>C With IBS-C  256 120 USA 62
CG/GG genotype with 
IBS-D 
 151 100 India 36
G allele with the total 
IBS  
G allele with the IBS-D  99 171 Korea 42
ADRA2C 
 
rs6846820 g.3766265T>C c.964–975:Del
 
With IBS-C
 
 256 120 USA 62
NXPH1 rs2349775 g.8718080G>A c.55-72558G>A With IBS-D
 
 935 639 USA, UK, 
Sweden 
63
SNPs in genes related to immune function 
IL10 rs1800896 g.206946897T>C c.-1117A>G Low producer 
genotype with IBS 
 230 450 UK 64
Low producer 
genotype with IBS 
 111 162 Netherlands 65
Low producer genotype  45 92 Mexico 66
 4
with IBS-D
GA genotype with IBS  71 140 Iran 67
A allele and AA 
genotype with IBS 
 45 137 Mexico 68, 69
AA+GA vs GG 
genotype with a 
lower IBS risk in 
Caucasian ethnicity 
 928 1363 China, India, 
Iran, Korea,  
Mexico,  
Netherlands, 
UK 
70
rs1800872 g.206946407T>G c.-627A>C CC vs GG genotype 
with a higher risk of 
IBS in Asian ethnicity 
 928 1363 China, India, 
Iran, Korea,  
Mexico,  
Netherlands, 
UK 
70
A allele with IBS  23 20 Mexico 71
rs1800871 g.206946634A>G c.-854T>C CC genotype with IBS-D - 50 50 Japan 72
TNFSF1
5 
rs4263839 g.117566440A>G c.210+1643T>C With IBS With IBS-C  861 1131 USA, Sweden 73
 With IBS With IBS-C  2894 3138 USA, UK, Iran, 
Belgium, 
India, 
Netherlands, 
Mexico, 
Sweden 
74
rs6478108 g.117558703C>T c.211-2855G>A With IBS-A  935 639 USA, UK, 
Sweden 
63
IBS-D lower MAF 
frequency 
37 IBS-D 
and 19 
IBS -C 
25 UK 75
rs6478109  g.117568766A>G c.-474T>C
rs7848647 g.117569046T>C c.-754A>G
rs4263839   g.117566440A>G, c.210+1643T>C With IBS-A  935 639 USA, UK, 
Sweden 
63
IL8 rs2227306 g.74607055C>T c.65-204C>T With IBS  45 137 Mexico 68, 69
rs2227307 g.74606669T>G c.64+230T>G With IBS  
IL6 rs1800795 g.22766645C>G c.-237C>G C allele  with PI-IBS  228 581 Canada 76
G allele with IBS  71 140 Iran 67
With IBS  23 20 Mexico 71
IL4 rs2070874 g.132674018C>T c.-33C>T CC genotype with IBS  71 140 Iran 67
rs2243250 g.132673462C>T c.-589C>T TT genotype with IBS  
TNFα rs1800629 g.31543031G>A c.-308G>A GA genotype with IBS  111 162 Netherlands 65
rs361525 g.31543101G>A c.-238G>A G allele and GG 
genotype with IBS 
 71 140 Iran 67
IL1R rs2234650 g.102758327C>T c.-83-12074C>T C allele with IBS  71 140 Iran 67
TLR9+ rs5743836 g.52260782A>G c.-1237T>C T allele with PI-IBS  228 581 Canada 76
rs352139 g.52258372T>C c.2848G>A A allele with PI-IBS  
 5
 
SNPs in genes involved in barrier integrity 
CDH1 rs16260 g.68737131C>A c.-160C>A A allele  with PI-IBS  228 581 Canada 76
CDC42 rs17837965 g.22394625A>G c.-176-5962A>G With IBS-C   935 639 USA, UK, 
Sweden 
63
SNPs in genes involved in bile acid synthesis, transport and excretion 
KLB rs17618244 g.39448529G>A p.R728Q G allele (Arg728) with 
IBS-D 
Accelerated transit in IBS-
D 
435 279 USA 77
G allele with increased bile 
acids synthesis and 
excretion 
94 30 USA 78
FGFR4 rs351855 g.177093242G>A c.1097+65G>A, Colonic tranist in IBS-D 435 279 USA 77
rs1966265 g.177089630G>A c.28G>A
 
*This SNP represents a polymorphic region consisting of an indel, i.e. either an insertion or a deletion, of 43 or 44 nucleotides, respectively. This SNP is commonly known as 
the 5-HTTLPR variant of the serotonin transporter SLC6A4 gene. The deletion allele is referred to as the S allele, the insertion allele is termed as the L allele, and hence the 
genotypes are usually called the LL, SL, and SS genotypes. 
 
 
Table 2 
 
miRNA Tissue Target gene Patients/Controls Disorder Quantitative Trait Reference 
hsa-miR29a↑ duodenum/colon GLUL  ↓ 19 IBS-D/10 IBS Permeability  ↑ 111
hsa-miR 29b↑ duodenum/colon CLDN1 ↓ 183/36 IBS-D Permeability  ↑ 112
hsa-miR 29b↑ duodenum/colon NKRF ↓ 183/36 IBS-D Permeability  ↑ 112
hsa-miR-150 ↑ blood AKT2* 12/31 IBS n/a 113
hsa-miR-342-3p ↑ blood unknown 12/31 IBS n/a 113
hsa-miR-199a↓ duodenum/colon TRPV1 ↑ 45/40 IBS-D Pain perception ↑ 114
AKT2 protein kinase , CLDN1 claudin1, GLUL glutamine synthetase, IBS-D diarrhea-predominant irritable bowel syndrome, n/a not applicable, NKRF NF-kappa-B-
repressing factor, TRPV1 transient receptor potential vanilloid type 1, * in silico prediction - not validated, ↓ down regulated, ↑ up regulated 
 
Gut microbiota 
Sex 
Genes 
Clinical phenotype 
Peripheral intermediate 
phenotypes (ENS) 
Peripheral intermediate 
phenotypes (GI function) 
Behavioural intermediate 
 phenotype 
Central neurobiological 
intermediate  phenotype 
Psychological stress 
Chronic abdominal 
pain/discomfort 
and altered bowel 
habits: IBS 
Emotional  
regulation 
Visceral sensation/ 
Pain modulation 
Infection/ 
dysbiosis 
Epigenetics 
Chronic fatigue, 
depression, anxiety 
Migraine, 
fibromylagia 
GI transit 
secretion 
Diet 
B
rain
-gu
t axis 
Smoking 
  Permeability 
SLC6A4 
SCN5A 
GRID2IP 
 
CDH1 
CDC42 
TNFSF15 
 
 
Altered immune function 
Aberrant neuronal function  
Increased visceral pain perception 
Altered secretomotor function 
Psychological comorbidity 
Anxiety 
Somatisation 
HTR3 
NXPH1 
 
Epithelial barrier 
Gut brain axis 
Microbiota 
Food antigens 
Innate immune cells  
T and B cells 
CLDN 
GLUL 
NKRF 
miR 29a/b, 
miR199a 
TRPV1 
 
